Jun 08, 2018
Microbiome Health Index(TM) Platform, Outcomes of Rebiotix's RBX7455 Oral Formulation To Be Featured in Rapid Fire and Poster Sessions at ASM Microbe 2018
Jun 04, 2018
Rebiotix Microbiota Restoration Therapy(TM) Products, Microbiome Health Index(TM) to Take Center Stage at Digestive Disease Week 2018
Jun 01, 2018
Rebiotix's President and CEO, Lee Jones to Participate in Microbiome-Focused Panel at the 2018 BIO International Convention
Mar 12, 2018
Rebiotix's Chief Scientific Officer, Ken Blount, Ph.D., to Present at Microbiome Therapeutics Europe
Feb 12, 2018
Rebiotix Develops Microbiome Health Index(TM) to Identify Indicators for Microbiome Restoration
Jan 09, 2018
Rebiotix Highlights 2017 Achievements and 2018 Objectives
Jan 05, 2018
Rebiotix and CoreBiome Collaborate on Evaluating Microbiomes of Patients Treated with Microbiota Restoration Therapy(TM)
Jan 04, 2018
Rebiotix Participating in Multiple Events During J.P. Morgan 36th Annual Healthcare Conference 2018 Week
Nov 15, 2017
Rebiotix to Present at 29th Annual Piper Jaffray Healthcare Conference
Nov 02, 2017
Rebiotix and the C Diff Foundation Applaud the State of Minnesota as it Declares November C. Difficile Infection Awareness Month
Oct 16, 2017
New Clinical Data and Microbiome Research from Rebiotix's Phase 2 Program for RBX2660 Highlighted at the World Congress of Gastroenterology at ACG2017
Oct 12, 2017
Rebiotix Announces New RBX2660 Data Including a Novel Microbiome Biomarker Analysis to be Presented at the World Congress of Gastroenterology at ACG2017
Oct 04, 2017
Presentations at ID Week(TM) 2017 Highlight Clinical Results and Microbiome Analysis of Patients Treated in Rebiotix's RBX2660 Phase 2 Studies
Sep 06, 2017
Rebiotix Appoints Edward S. Burd, Ph.D., to Head of Regulatory Affairs
Aug 23, 2017
Rebiotix to Present at BioCentury's 24th Annual NewsMakers in the Biotech Industry Conference
Aug 07, 2017
Rebiotix Announces First Patient Enrolled in Phase 3 Clinical Trial of RBX2660 for the Prevention of Recurrent Clostridium difficile Infection
Jun 20, 2017
Rebiotix Continues Management Team Expansion with Appointment of Greg Fluet as Chief Business Officer
Jun 07, 2017
Rebiotix Data Presented at ASM Microbe 2017 Show RBX2660 Treated Patients' Clinical Success Correlates with Improved Microbiome Diversity
Jun 01, 2017
Rebiotix's Phase 3-Ready RBX2660 to be Featured in Multiple Posters at ASM Microbe 2017